Phase II randomized double-masked crossover test of rhPRG4 (450 µg/mL) eye drops versus vehicle for ocular GVHD dry eye

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an 84-day, randomized (1:1), double-masked, crossover Phase II trial in adults with moderate to severe ocular graft‑versus‑host disease–related dry eye. Each participant receives both rhPRG4 (450 µg/mL) and matching vehicle eye drops for 28 days each, separated by a 14-day vehicle washout period, with treatment order randomized. Key entry requirements include symptom thresholds on VAS (dryness ≥40 mm and average symptom score ≥25 mm) and an Oxford corneal fluorescein staining score ≥2 in the worse eye. The trial measures safety and efficacy outcomes including symptom scores and corneal staining to compare rhPRG4 against vehicle within the same patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Have the ability to comprehend and provide a signed and dated consent form.
2. Are 18-80 years of age at time of consent;
3. Have been diagnosed with oGVHD for at least 3 months prior to giving informed consent to participate in the trial;
4. Current use of artificial tears for the treatment of oGVHD related dry eye;
5. Have been stably using systemic medications for at least 14 days prior to Visit 1;
6. VAS Eye Dryness (100-point scale) score ≥ 40 mm;
7. Average VAS score for all symptoms of dry eye (dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia) ≥ 25 mm, none \< 5 mm;
8. Have Oxford corneal fluorescein staining grade of ≥ 2 using the Oxford scale in the worst performing eye
9. Stated willingness to comply with all study procedures, attend all scheduled clinic visits, and continue participation for the duration of the study;
10. Ability to self-administer study medication and willingness to adhere to the medication regimen.

Exclusion Criteria:

Are currently or have a history of any ocular or systemic disorder or condition other than dry eye that based on investigator judgment will interfere with the interpretation of the study results. Examples of ocular or systemic disorders or conditions include active ocular infection, conjunctivochalasis, superior limbic keratoconjunctivitis, limbal stem cell deficiency, allergic conjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, anterior basement membrane dystrophies, neurotrophic keratitis, corneal dystrophy, exposure keratitis, moderate to severe blepharitis, ocular trauma, progressive or degenerative corneal conditions, uveitis, and systemic infection; 2. History of any ocular surgery (including laser or refractive surgical procedures) or therapeutic medical devices in either eye within 30 days before study enrollment. Therapeutic medical devices include trigeminal stimulation, meibomian glad warming (excepting at home masks) or expression, intense pulsed light, low level light therapy, etc. Ocular surgeries include laser or refractive surgical procedures, insertion of punctal or punctal cauterization; Ocular surgery will not be allowed during study participation; 3. Initiation of new therapeutic modalities within 14 days of Visit 1; 4. Have a known hypersensitivity to one of the components of the study or procedural medications; 5. Have participated in another clinical study at the same time as the present study or within 30 days of the Visit 1; 6. Have a history of drug, medication or alcohol abuse or addiction; 7. Are females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) who meet any one of the following conditions:

1. are currently pregnant or,
2. have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
3. intend to become pregnant during the entire course of and 30 days after the study treatment periods, or,
4. are breast-feeding or,
5. not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods; 8. Per the discretion of the investigator or designee, history of a serious physical or mental disorder that prevents the subject from attending study visits, complying with study-related procedures, and/or prevents the subject's ability to make decisions on their own; 9. Any other surgical or medical condition or finding that in the opinion of the investigator would compromise the subject's safety or participation in the study.

Where it's running

• Ota
  Brisbane, Queensland, Australia Recruiting
• Royal Melbourne Hospital
  Melbourne, Victoria, Australia Recruiting
• Sydney Eye Hospital
  Sydney, New South Wales, Australia Not yet recruiting

Study contacts

• Study coordinator: Edward CEO
• Email: etruitt@lubris.net
• Phone: 6193394016

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• d-MAPPS Ophthalmic Solution for adults with chronic oGVHD

  This Phase 3 trial tests whether d-MAPPS ophthalmic drops can help adults with chronic ocular graft-versus-host disease compared with a placebo-like vehicle over 90 days.

  Recruiting at 4 sites Phase 3 Regenerative Ocular Immunobiologics LLC · Beverly Hills, California and 4 other locations · NCT07776210

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• Ruxolitinib for Graft-Versus-Host Disease in Clinical Practice

  This study tests how well Jakavi (ruxolitinib) works and how safe it is for people with acute or chronic GVHD being treated in real-world medical settings.

  Recruiting Novartis · Tokyo · NCT07594587

• Moxibustion with second-line treatment for steroid-refractory acute graft-versus-host disease after transplant

  This study will test whether adding moxibustion to standard second-line drug therapy helps people aged 14–65 with steroid-refractory gastrointestinal acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07572669

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.